



Spread of Exotoxin S and Protease IV Genes and Their Correlation with Antibiotics Resistance Among the *Pseudomonas aeruginosa* Strains Isolated from Patients with Corneal Keratitis

Seyedeh Bahareh Mirani¹, Sara Bijari¹, Amin Sepehrizadeh¹, Bahareh Rahimian Zarif^{1,*}

¹Department of Biology, Sa.C., Islamic Azad University, Sanandaj, Iran

*Corresponding Author: Department of Biology, Sa.C., Islamic Azad University, Sanandaj, Iran. Email: bahareh.rahimianzarif@iau.ac.ir

Received: 22 November, 2024; Revised: 6 June, 2025; Accepted: 5 July, 2025

Abstract

Background: *Pseudomonas aeruginosa* is a leading nosocomial pathogen. Its complex virulence mechanisms and rapid adaptation to drugs/antimicrobials are well known.

Objectives: In this work, we searched for exotoxin S (exoS) and protease IV (piv) genes in *P. aeruginosa* resistant strains from corneal keratitis patients.

Methods: *Pseudomonas aeruginosa* strains were isolated by taking samples from the eyes of patients with keratitis and cultured on McConkey and Citrimide, followed by biochemical tests. Then, exoS and piv genes were identified through the PCR process. Bacterial resistance to imipenem, piperacillin, ciprofloxacin, tobramycin, ceftazidime, gentamicin, ticarcillin, amikacin, and cefixime was measured via the disc diffusion test. Finally, logistic regression analysis was performed using SPSS V23.

Results: Out of the entire set of ocular specimens, 72 isolates (41.14%) exhibited positive culture results. Among culture-positive isolates, 15 (20.83%) were identified as *P. aeruginosa* via biochemical tests. The results showed resistance to imipenem, piperacillin, ciprofloxacin, tobramycin, ceftazidime, gentamicin, ticarcillin, amikacin, and cefixime in 66.7%, 60%, 66.7%, 80%, 46.7%, 53.3%, 80%, 53.3%, and 93.3%, respectively. The prevalence of exoS and piv genes was 53.3% and 86.7%, respectively. The findings of our study demonstrate a significant correlation between the exoS gene and individual resistance to ceftazidime and gentamicin agents. No significant correlation between the piv gene and antibiotic resistance was observed.

Conclusions: The prevalence of multi-drug resistance among *P. aeruginosa* strains obtained from patients with keratitis was found to be 86.66%. This finding underscores the need to identify novel drug compounds for these bacteria and modify antibiotic consumption patterns within this specific geographic region. The piv gene is present in the majority of keratitis strains, suggesting its significance in the pathogenicity of the bacteria. The identification of piv and exotoxin inhibitors can also provide assistance. The exoS-gentamicin/ceftazidime link is the key novel finding of this study.

Keywords: Exotoxin S, Protease IV, Antibiotics Resistance, *Pseudomonas aeruginosa*, Corneal Keratitis

1. Background

Pseudomonas aeruginosa is a pathogenic bacterium that is gram-negative (1). *Pseudomonas aeruginosa* is responsible for various infections, including pneumonia, surgical site infections, urinary tract infections, and bacteremia. It is estimated to have a prevalence of 7.1% - 7.3% among all patients (2). Keratitis is an ophthalmological condition characterized by

inflammation of the cornea, leading to potential impaired vision in severe instances. This disease can arise from microbial infection, including bacteria, fungi, viruses, or protozoans, as well as non-infectious factors like eye trauma, exposure to chemicals, or ultraviolet light (3). One of the bacteria that causes keratitis is *P. aeruginosa*. *Pseudomonas aeruginosa* demonstrates adaptability to unfavorable conditions in hosts by secreting several virulence factors, which play a

Copyright © 2025, Journal of Clinical Research in Paramedical Sciences. This open-access article is available under the Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0) International License (<https://creativecommons.org/licenses/by-nc/4.0/>), which allows for the copying and redistribution of the material only for noncommercial purposes, provided that the original work is properly cited.

How to Cite: Mirani S B, Bijari S, Sepehrizadeh A, Rahimian Zarif B. Spread of Exotoxin S and Protease IV Genes and Their Correlation with Antibiotics Resistance Among the *Pseudomonas aeruginosa* Strains Isolated from Patients with Corneal Keratitis. J Clin Res Paramed Sci. 2025; 14 (2): e157421. <https://doi.org/10.5812/jcrps-157421>.

crucial role in achieving effective infection and inducing disease (4). Lipopolysaccharide (LPS) serves as a crucial surface structural element that safeguards the external leaflet and poisons host cells. The lipid A in LPS exhibits endotoxicity, which facilitates tissue injury, attachment, and detection by host receptors. The LPS has the potential to be associated with antibiotic resistance and the production of biofilms (5, 6). Furthermore, the development of biofilms is linked to drug resistance, which is attributed to the flagellum, pili, and other adhesins. In addition, there exist six distinct secretion systems, including flagella (related to the T6SS), pili (associated with the T4SS), and the multi-toxin components type 3 secretion system (T3SS). These systems play crucial roles in several biological processes such as host colonization, adhesion, swimming, and swarming, as they respond to chemotactic signaling (7). The presence of T3SS exoenzymes was identified as significant virulence factors that trigger *P. aeruginosa* keratitis. The T3SS is a specialized protein export system that establishes a needle-shaped complex between bacterial and host cells to facilitate the transportation and release of four exotoxins, namely exotoxin S (exoS), exoT, exoU, and exoY (8). The exoS is a cytotoxin consisting of 453 amino acids (48 kDa) that demonstrates the ability to activate both GTPase-activating protein (GAP) and ADP ribosyl transferase (ADPRT) enzymes (8).

Protease IV (piv), sometimes referred to as lysyl endopeptidase, is a 26 kDa iron-regulated enzyme that belongs to the chymotrypsin family of proteins. It is encoded by the prpL gene. The activation of the host immunological defense system is initiated by piv via the degradation of fibrinogen, plasminogen, and immunoglobulin G, as well as the inactivation of complement components, including C3 and C1 (9). The corneal pathogenicity of *P. aeruginosa* has been associated with several virulence factors, one of which is the synthesis of the extracellular enzyme piv. The correlation between tissue damage during keratitis and the production of this enzyme has been demonstrated in many animal models (10, 11).

Addressing the escalating issue of antibiotic resistance is an important challenge that afflicts contemporary civilization (12). The multifaceted nature of the antibacterial action employed by *P. aeruginosa* poses challenges in effectively eliminating the bacteria from healthcare environments. *Pseudomonas aeruginosa*'s outer membrane has several porins that regulate cellular mobility, as well as efflux pumps that actively expel antimicrobial agents. In addition,

compared to other gram-negative bacteria, it exhibits lower permeability to antibiotics (13).

It is known that resistance and virulence genes are also transmitted simultaneously. To achieve substantial advancements in addressing the global issue of antibiotic resistance and virulence, it is imperative to adopt a novel approach that acknowledges the interconnectedness of their regulation and transmission. The facilitation of gene expression, transfer, and regulation is enhanced not only when both genetic elements are co-located on a plasmid but also when bacteria exist in a biofilm state (14, 15). By determining the relationship between different virulence genes and antibiotic resistance, it is possible to find strategies to prevent the further transmission of these genes together.

2. Objectives

Therefore, this study aimed to investigate exoS and piv genes among *P. aeruginosa* resistant strains isolated from patients with corneal keratitis.

3. Methods

3.1. Sampling and Culture

The ethics committee and institutional review board of Islamic Azad University Sanandaj Branch granted approval for this study, which adhered to the principles outlined in the Declaration of Helsinki. An analysis of all patients with a diagnosis of corneal ulcer at Imam Khomeini Hospital (Kermanshah, Iran) was performed. All corneal ulcers, with the exception of peripheral infiltrates less than 3 mm (as they are less likely to be caused by microbial keratitis or require cultures) and without any indication of corneal thinning upon slit lamp examination, underwent corneal scraping. Corneal scrapes were acquired subsequent to the administration of topical anesthesia. Corneal samples were obtained using a sterile scalpel blade under the observation of a slit lamp biomicroscope. Capillary ulcer samples were utilized for the direct inoculation of culture media, specifically MacConkey and Cetrimide agar. The plates were then incubated at a temperature of 37°C for 48 hours. The *P. aeruginosa* strains were identified via microbiological tests (Catalase test) (16) to detect the presence of the enzyme catalase, which breaks down hydrogen peroxide. Positive results (bubbles) indicate the presence of catalase.

3.2. Antibiotics Susceptibility Testing

DNA was extracted using the DNA extraction kit (Sinaclon, Iran) according to the manufacturer's instructions. Antibiotic susceptibility was confirmed by the disk diffusion technique on Muller-Hinton medium (Merck, Germany), performed according to the Clinical Laboratory Standard Institute (CLSI) guidelines. Paper disks were impregnated with antibiotics (Padtanteb, Iran): Imipenem (10 µg), Piperacillin (100 µg), Ciprofloxacin (5 µg), Tobramycin (10 µg), Ceftazidime (30 µg), Gentamicin (10 µg), Ticarcillin (75 µg), Amikacin (30 µg), Cefixime (5 µg). They were incubated overnight at 37°C. The diameter of the zone of inhibition was measured, and the results were interpreted as sensitive, intermediate resistant, or resistant, based on CLSI guidelines (17).

3.3. Virulence Gene Detection

The PCR technique was employed to confirm the existence of the *exoS* and *piv* genes, utilizing the primers and conditions outlined in Table 1. Each *P. aeruginosa* isolate was subjected to screening for the presence of virulence genes in a 20 µL reaction volume PCR assay, employing the Master mix (Sinaclon, Iran), and adding 0.4 µM of forward and reverse primers per gene to the amplified, nuclease-free water and extracted genomic DNA. The amplification process was conducted using a Labcycler (Sensoquest, Germany) with the following conditions: 94°C for 3 minutes, followed by 35 cycles of amplification at 94°C for 30 seconds, 60°C for 60 seconds, 72°C for 60 seconds, and a final step of extension at 72°C for 7 minutes. Agarose gel electrophoresis was performed on the PCR products using a 1.5% agarose gel in a 1x concentrated TBE buffer (Sinaclon, Iran). The electrophoresis was conducted at 80 V for a duration of 1 hour using a 50 bp DNA ladder (Sinaclon, Iran). Subsequently, the DNA bands were observed and measured using UV light.

3.4. Statistical Analysis

In this research, the data were entered into SPSS software (SPSS Inc., Chicago, Illinois, USA) version 22. Statistical analysis was performed using logistic regression. In addition to the P value, logistic regression also provides us with odds ratio data. This data shows the strength of the correlation between the independent and dependent variables.

4. Results

4.1. Samples and Resistance Pattern

A total of 175 corneal cultures were conducted. The patients had an average age of 58.4 ± 19.3 years, and 114 (65.14%) were male. Out of the entire set of ocular specimens, 72 isolates (41.14%) exhibited positive culture results. Among culture-positive isolates, 15 (20.83%) were identified as *P. aeruginosa* via biochemical tests. Figure 1 displays the distribution of antibiotic resistance profiles. The antibiotic resistance rates of *P. aeruginosa* were found to be highest against cefixime (93.3%) and lowest against ceftazidime (46.7%).

4.2. Relationship Between Exotoxin S and Protease IV Genes and Antibiotic Resistance

The results showed that 53.3% of the strains have the *exoS* gene and 86.7% have the *piv* gene (Figure 2). This study also examined the correlation between the existence of virulence genes (*exoS* and *piv*) and antibiotic resistance. The frequency of genes associated with antibiotic resistance in strains is depicted in Figure 3. Table 2 presents the statistical analysis conducted using logistic regression. The analysis of the table reveals that there is no significant correlation between the existence of the *piv* gene and antibiotic resistance ($P > 0.05$). Regarding the *exoS* gene, it is noteworthy that a significant correlation exists between the gene's existence and resistance to ceftazidime ($P = 0.033$, OR: 18, CI = 1.267 - 255.744) and gentamicin ($P = 0.014$, OR: 42, CI = 2.136 - 825.715). Strains that are resistant to ceftazidime and gentamicin are more likely to possess the *exoS* gene, indicating a direct association between the *exoS* gene and resistance to these antibiotics.


5. Discussion

Bacterial keratitis is a prevalent condition affecting the corneal tissue, posing a significant risk to vision. The occurrence of endophthalmitis and subsequent eye loss can be attributed to the ineffective or delayed treatment of this prevalent infectious eye disease. Bacterial keratitis is caused by a significant multitude of microorganisms. Previously, *Streptococcus pneumoniae* was the most frequently found pathogen in bacterial corneal ulcers. However, the prevalence of *Pseudomonas* and *Staphylococcus* infections has risen due to the growing use of contact lenses (20, 21). *Pseudomonas aeruginosa* is a globally significant pathogen that exhibits a notable degree of genetic variation. Most isolates have virulence genes that are involved in the production of pyocyanin, phospholipase C, *piv*, alkaline protease, elastase B, and some exoenzymes (22). The virulence feature of the *P. aeruginosa* strain is a multifaceted subject. The genotype makeup of a particular strain may be a significant factor in

Table 1. Primer Sequences and Annealing Temperature (18, 19)

| PCR Product | Sequence (5' → 3') | Amplicon Size (bp) | Annealing Temperature (°C) |
|-------------|----------------------|--------------------|----------------------------|
| exoS | | 118 | 62 |
| Forward | GCGAGGTCAGCAGAGTATCG | | |
| Reverse | TTCGGCGTCACTGTGGATGC | | |
| piv | | 600 | 60 |
| Forward | GCTTCAGTTTGGTCAGGAGC | | |
| Reverse | CAGGCTCATTGAGTGTGGAA | | |

Abbreviations: exoS, exotoxin S; piv, protease IV.

**Figure 1.** Antibiotic resistance profiles of strains based on Clinical Laboratory Standard Institute (CLSI) standard guideline

determining its varying pathogenicity potential and complex drug-resistance spectrum, particularly in a specific subgroup of strains. The results showed resistance to imipenem, piperacillin, ciprofloxacin, tobramycin, ceftazidime, gentamicin, ticarcillin, amikacin, and cefixime in 66.7%, 60%, 66.7%, 80%, 46.7%, 53.3%, 80%, 53.3%, and 93.3%, respectively. The 93.3% cefixime resistance in *P. aeruginosa* is highly unusual, suggesting a combination of intrinsic and acquired resistance mechanisms. While *P. aeruginosa* is known for its inherent resistance, the specific high resistance to cefixime likely involves a combination of its restricted outer membrane permeability, efflux pumps, and potentially acquired beta-lactamases (23).

In the study conducted by Alamri et al., the resistance rates were as follows: 33.3% for aztreonam, 36.7% for imipenem, 16.7% for meropenem and ceftazidime, 13.3% for ciprofloxacin, and 10% for gentamicin and cefepime (24). Based on the differences in the type of clinical samples and geographical region, variations in the resistance pattern of the strains can be observed. Mirzaei et al. conducted a study in Iran which documented resistance rates of 64%, 52%, 58.7%, and 62.7% to imipenem, gentamicin, ceftazidime, and ciprofloxacin, respectively (25). The findings of the Mirzaei et al. study exhibit a higher degree of similarity to the current study due to the shared geographical context of Iran. If there is a difference in the results, it




Figure 2. Prevalence of exotoxin S (*exoS*) and protease IV (*piv*) genes (A), gel electrophoresis *exoS* (B), and gel electrophoresis *piv* (C).




Figure 3. Frequency of exotoxin S (*exoS*), and protease IV (*piv*) genes associated with antibiotic resistance in strains

can be due to the difference in the type of sample (25). A multiple-drug resistance (MDR) rate of 86.66% is a cause for concern, even when aligned with regional data. Potential biases in the data may include differences between hospital-acquired (nosocomial) and community-acquired strains, as well as sampling and testing methodologies.

Corneal epithelial cells exhibit varying effects of T3SS effectors based on their genotypes. Strains possessing the *exoS* genotype have the ability to infiltrate and proliferate within corneal epithelial cells, both in vitro and in vivo. The survival of *P. aeruginosa* within corneal

epithelial cells was revealed to be dependent on the presence of a functioning T3SS (8). The pathogenicity of *P. aeruginosa* in experimental keratitis has been attributed to the type III effector ExoU, which has been found to trigger fast lysis of epithelial cells and macrophages. Cytotoxic strains, namely *exoU*⁺ strains, have the ability to harm the epithelia on a corneal surface that is not damaged, as long as there is prolonged contact with the bacteria. *ExoU*⁺ strains may exhibit more adhesion under contact lens wear circumstances (26).

Table 2. Logistic Regression Results to Determine the Association Between Virulence Genes and Antibiotic Resistance

| Antibiotic Resistance | P-Value | OR | CI (95%) | |
|-----------------------|---------|-------|----------|---------|
| | | | Lower | Upper |
| Imipenem | | | | |
| exoS | 0.468 | 2.250 | 0.251 | 20.131 |
| piv | 0.598 | 2.250 | 0.111 | 45.723 |
| Piperacillin | | | | |
| exoS | 0.403 | 0.4 | 0.47 | 3.424 |
| piv | 0.999 | - | - | - |
| Ciprofloxacin | | | | |
| exoS | 0.999 | - | - | - |
| piv | 0.999 | - | - | - |
| Tobramycin | | | | |
| exoS | 0.999 | - | - | - |
| piv | 0.999 | - | - | - |
| Ceftazidime | | | | |
| exoS | 0.033 | 18 | 1.267 | 255.744 |
| piv | 0.999 | - | - | - |
| Gentamicin | | | | |
| exoS | 0.014 | 42 | 2.136 | 825.715 |
| piv | 0.919 | 1.167 | 0.059 | 22.937 |
| Ticarcillin | | | | |
| exoS | 0.448 | 2.8 | 0.196 | 40.057 |
| piv | 0.999 | - | - | - |
| Amikacin | | | | |
| exoS | 0.782 | 0.75 | 0.98 | 5.768 |
| piv | 0.919 | 1.167 | 0.059 | 22.937 |
| Cefixime | | | | |
| exoS | 0.999 | - | - | - |
| piv | 0.999 | - | - | - |

Abbreviations: OR, odds ratio; CI, confidence interval; exoS, exotoxin S; piv, protease IV.

The correlation between tissue damage during keratitis and the production of piv has been demonstrated in many animal models. Research has demonstrated that piv exhibits the ability to degrade a diverse range of host proteins, encompassing host defense components such as complement and IgG class immunoglobulin (10). The presence of ring abscess lesions in pseudomonal keratitis has been found to be associated with piv (27). Therefore, the isolated strains had a high prevalence of piv (86.7% of the piv gene).

While piv has been shown to be important for pathogenesis, studies indicate that there's no significant correlation between its presence and antibiotic resistance. This means that the loss or presence of piv does not directly impact an organism's ability to develop resistance to antibiotics (28). The prevalence of the exoS gene in the present study was 53.3%. The frequency of antibiotic resistance and virulence genes can vary in each geographical region. In other studies

conducted in Iran, the incidence of exoS was shown to be higher. In a study conducted by Fazeli and Momtaz (29), the incidence of exoS in isolates from Iranian hospital infections was reported as 67.64%. Dadmanesh et al. (30) published a rate of 73.91% for exoS. Additionally, Shokrzadeh et al. (31) found that the frequency of the exoS gene in Sari, Iran was 77.8%. The elevated incidence of exoS observed in our investigation may be attributed to the substantial clonal variability exhibited by the isolates. The lower frequency of exoS in the present study could be because the studied strains had a more exoU+-exoS- profile.

Numerous investigations have been conducted to examine the potential association between the virulence and resistance spectrum of *P. aeruginosa*, yielding inconsistent findings. Previous reports have shown a positive correlation between the exoU+ genotype of *P. aeruginosa* and a moderate resistance phenotype, as well as a negative correlation with

extended-drug resistance (XDR). Additionally, it has been demonstrated that the *exoU*⁺ genotype is more likely to be resistant to fluoroquinolones when there is a *gyrA* mutation and overexpression of the efflux pump (32).

In *P. aeruginosa*, there's a relationship between the virulence factor *exoS* and the development of carbapenem resistance. While not directly causing resistance, *exoS*, along with other virulence factors like *exoY* and *exoT*, can contribute to the pathogenicity of *P. aeruginosa*, particularly in carbapenem-resistant strains. Moreover, *exoS* expression is often co-expressed with other virulence factors like *exoU*, and this co-expression can be linked to enhanced virulence in carbapenem-resistant strains (33). In contrast to the present study, some previous studies reported that the *exoS* genotype has a relation to the phenotype of carbapenem resistance, suggesting that *exoS* may be incongruous with genes associated with carbapenemase production to a certain degree in clinical strains (32, 34, 35). They reported that given the intricate regulatory network regulating virulence and drug resistance in *P. aeruginosa*, it is possible that the feasible antagonism between *exoS* and carbapenem resistance could confer advantages to the bacteria, enabling them to achieve prolonged survival and infection.

In the present study, there was no significant relationship between the *exoS* gene and the phenotype of resistance to imipenem (carbapenem). This difference can be related to the fact that only imipenem was used as a carbapenem antibiotic and also the type of samples is different. In some bacteria, a potential antagonism, or conflict, exists between the presence of the virulence gene *exoS* and carbapenemase genes. Specifically, *exoS* was found to be less frequently detected in carbapenem-resistant *Pseudomonas aeruginosa* (CRPA) strains carrying carbapenemase genes, suggesting an incompatibility between the two. This finding hints at a complex relationship between virulence and resistance in these bacteria (32).

In our study, a significant relationship was observed between the presence of the *exoS* gene and resistance to ceftazidime (cephalosporin) and gentamicin (aminoglycoside). The utilization of antivirulence strategies, which involve combating bacterial infections by targeting virulence factors – the components that enable bacteria to cause disease – rather than directly killing the bacteria themselves, has emerged as a novel approach to solving the issue of resistant bacterial strains (22). Through the analysis of the distribution and function of virulence factors in bacteria, it is feasible to identify chemicals that can effectively hinder their

activity. Moreover, by establishing a correlation between virulence genes and antibiotic resistance, the simultaneous use of antivirulence agents and antibiotics that exhibit resistance can be avoided.

Biofilm formation, though unmeasured in our study, can significantly impact gene-resistance links. Biofilms, dense microbial communities, promote horizontal gene transfer (HGT), facilitating the rapid spread of resistance genes within and between microbial populations. This can lead to increased antibiotic resistance and a broader range of resistance mechanisms compared to planktonic (single-cell) growth (36).

The main limitations of our work were the small number of available samples, which limits statistical power and generalizability, and the lack of mechanistic insights into how *exoS* might drive resistance to ceftazidime/gentamicin.

The strains of *P. aeruginosa* isolated from keratitis patients exhibit high antibiotic resistance, with 86.66% of them showing MDR. This finding underscores the need to identify novel drug compounds for these bacteria and modify antibiotic consumption patterns (e.g., stewardship strategies) within this specific geographic region. Keratitis strains mostly possess the *piv* gene, highlighting the importance of this virulence gene in their pathogenicity. The production of *exoS* in strains also has a prevalence of 53.3%. The findings of our study demonstrate a significant correlation between the *exoS* gene and individual resistance to ceftazidime and gentamicin agents. This link should be taken into account when analyzing the outcomes of infection. No significant correlation between the *piv* gene and antibiotic resistance was observed. Further research with larger sample sizes and in-depth investigation of the mechanism is warranted in the future. Finally, the identification of *piv* and exotoxin inhibitors can also provide assistance. For future investigations, biofilm assays are suggested for a deeper exploration of the correlation with resistance.

Footnotes

Authors' Contribution: Study concept and design: B. R. Z.; Acquisition of data: S. B. M.; Analysis and interpretation of data: A. S.; Drafting of the manuscript: S. B.; Critical revision of the manuscript for important intellectual content: S. B.; Statistical analysis: S. B. M.; Administrative, technical, and material support: B. R. Z.; Study supervision: B. R. Z.

Conflict of Interests Statement: The authors declare no conflict of interest.

Data Availability: No new data were created or analyzed in this study. Data sharing does not apply to this article.

Ethical Approval: This study is approved under the ethical approval code of [IR.IAU.SDJ.REC.1403.098](#) from Islamic Azad University, Sanandaj Branch.

Funding/Support: The Islamic Azad University of Sanandaj financially supported this study.

References

- Tuon FF, Dantas LR, Suss PH, Tasca Ribeiro VS. Pathogenesis of the *Pseudomonas aeruginosa* Biofilm: A Review. *Pathogens*. 2022;**11**(3). [PubMed ID: 35335624]. [PubMed Central ID: PMC8950561]. <https://doi.org/10.3390/pathogens11030300>.
- Reynolds D, Kollef M. The Epidemiology and Pathogenesis and Treatment of *Pseudomonas aeruginosa* Infections: An Update. *Drugs*. 2021;**81**(18):2117-31. [PubMed ID: 34743315]. [PubMed Central ID: PMC8572145]. <https://doi.org/10.1007/s40265-021-01635-6>.
- Hilliam Y, Kaye S, Winstanley C. *Pseudomonas aeruginosa* and microbial keratitis. *J Med Microbiol*. 2020;**69**(1):3-13. [PubMed ID: 31750813]. <https://doi.org/10.1099/jmm.0.001110>.
- Vidaillac C, Chotirmall SH. *Pseudomonas aeruginosa* in bronchiectasis: infection, inflammation, and therapies. *Expert Rev Respir Med*. 2021;**15**(5):649-62. [PubMed ID: 33736539]. <https://doi.org/10.1080/17476348.2021.1906225>.
- Park WS, Lee J, Na G, Park S, Seo SK, Choi JS, et al. Benzyl Isothiocyanate Attenuates Inflammation Activation in *Pseudomonas aeruginosa* LPS-Stimulated THP-1 Cells and Exerts Regulation through the MAPKs/NF-kappaB Pathway. *Int J Mol Sci*. 2022;**23**(3). [PubMed ID: 35163151]. [PubMed Central ID: PMC8835927]. <https://doi.org/10.1039/jims23031228>.
- Chambers JR, Cherny KE, Sauer K. Susceptibility of *Pseudomonas aeruginosa* Dispersed Cells to Antimicrobial Agents Is Dependent on the Dispersion Cue and Class of the Antimicrobial Agent Used. *Antimicrob Agents Chemother*. 2017;**61**(12). [PubMed ID: 28971863]. [PubMed Central ID: PMC5700346]. <https://doi.org/10.1128/AAC.00846-17>.
- Qin S, Xiao W, Zhou C, Pu Q, Deng X, Lan L, et al. *Pseudomonas aeruginosa*: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. *Signal Transduct Target Ther*. 2022;**7**(1):199. [PubMed ID: 35752612]. [PubMed Central ID: PMC9233671]. <https://doi.org/10.1038/s41392-022-01056-1>.
- Yang JJ, Tsuei KC, Shen EP. The role of Type III secretion system in the pathogenesis of *Pseudomonas aeruginosa* microbial keratitis. *Tzu Chi Med J*. 2022;**34**(1):8-14. [PubMed ID: 35233350]. [PubMed Central ID: PMC8830546]. https://doi.org/10.4103/tcmj.tcmj_47_21.
- Prasad ASB, Shruptha P, Prabhu V, Srujan C, Nayak UY, Anuradha CKR, et al. *Pseudomonas aeruginosa* virulence proteins pseudolysin and protease IV impede cutaneous wound healing. *Lab Invest*. 2020;**100**(12):1532-50. [PubMed ID: 32801335]. [PubMed Central ID: PMC7683349]. <https://doi.org/10.1038/s41374-020-00478-1>.
- Caballero A, Thibodeaux B, Marquart M, Traidej M, O'Callaghan R. *Pseudomonas* keratitis: protease IV gene conservation, distribution, and production relative to virulence and other *Pseudomonas* proteases. *Invest Ophthalmol Vis Sci*. 2004;**45**(2):522-30. [PubMed ID: 14744894]. <https://doi.org/10.1167/iov.03-1050>.
- O'Callaghan R, Caballero A, Tang A, Bierdeman M. *Pseudomonas aeruginosa* Keratitis: Protease IV and PASP as Corneal Virulence Mediators. *Microorganisms*. 2019;**7**(9). [PubMed ID: 31443433]. [PubMed Central ID: PMC6780138]. <https://doi.org/10.3390/microorganisms7090281>.
- Askandar RH, Sharifi F, Shayan S, Mohammadi H, Rahimi A, Ardalan N, et al. Early Blockage of Mycobacterium Tuberculosis Cell-wall Synthesis via EchA6 Inhibition to Overcome Resistance Strain: Insights from Umbrella Sampling Simulations. *Current Bioactive Compounds*. 2023;**19**(10). <https://doi.org/10.2174/1573407219666230614163801>.
- Plokarz D, Bierowiec K, Rypula K. Screening for Antimicrobial Resistance and Genes of Exotoxins in *Pseudomonas aeruginosa* Isolates from Infected Dogs and Cats in Poland. *Antibiotics (Basel)*. 2023;**12**(7). [PubMed ID: 37508322]. [PubMed Central ID: PMC10376396]. <https://doi.org/10.3390/antibiotics12071226>.
- Schroeder M, Brooks BD, Brooks AE. The Complex Relationship between Virulence and Antibiotic Resistance. *Genes (Basel)*. 2017;**8**(1). [PubMed ID: 28106797]. [PubMed Central ID: PMC5295033]. <https://doi.org/10.3390/genes8010039>.
- Yazdanpour Z, Tadjrobehkar O, Shahkhal M. Significant association between genes encoding virulence factors with antibiotic resistance and phylogenetic groups in community acquired uropathogenic *Escherichia coli* isolates. *BMC Microbiol*. 2020;**20**(1):241. [PubMed ID: 32758126]. [PubMed Central ID: PMC7409443]. <https://doi.org/10.1186/s12866-020-01933-1>.
- Soleimani M, Tabatabaei SA, Masoumi A, Mirshahi R, Ghahvechian H, Tayebi F, et al. Infectious keratitis: trends in microbiological and antibiotic sensitivity patterns. *Eye (Lond)*. 2021;**35**(11):3110-5. [PubMed ID: 33469134]. [PubMed Central ID: PMC8526825]. <https://doi.org/10.1038/s41433-020-01378-w>.
- Smith EC, Brigman HV, Anderson JC, Emery CL, Bias TE, Bergen PJ, et al. Performance of Four Fosfomycin Susceptibility Testing Methods against an International Collection of Clinical *Pseudomonas aeruginosa* Isolates. *J Clin Microbiol*. 2020;**58**(10). [PubMed ID: 32669380]. [PubMed Central ID: PMC7512173]. <https://doi.org/10.1128/JCM.01121-20>.
- Khodayary R, Nikokar I, Mobayen MR, Afrasiabi F, Araghian A, Elmi A, et al. High incidence of type III secretion system associated virulence factors (exoenzymes) in *Pseudomonas aeruginosa* isolated from Iranian burn patients. *BMC Res Notes*. 2019;**12**(1):28. [PubMed ID: 30646938]. [PubMed Central ID: PMC6334392]. <https://doi.org/10.1186/s13104-019-4071-0>.
- Kuypers J, Wright N, Ferrenberg J, Huang ML, Cent A, Corey L, et al. Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. *J Clin Microbiol*. 2006;**44**(7):2382-8. [PubMed ID: 16825353]. [PubMed Central ID: PMC1489473]. <https://doi.org/10.1128/JCM.00216-06>.
- Utlü B, Ondas O, Yildirim M, Bayrakceken K, Yildirim S. *Pseudomonas aeruginosa* Keratitis in Rats: Study of the Effect of Topical 5% Hesperidin Practice on Healing. *Eurasian J Med*. 2023;**55**(1):64-8. [PubMed ID: 36861869]. [PubMed Central ID: PMC10081028]. <https://doi.org/10.5152/eurasianjmed.2023.22234>.
- Ung L, Wang Y, Vangel M, Davies EC, Gardiner M, Bispo PJM, et al. Validation of a Comprehensive Clinical Algorithm for the Assessment and Treatment of Microbial Keratitis. *Am J Ophthalmol*. 2020;**214**:97-109. [PubMed ID: 31899203]. <https://doi.org/10.1016/j.ajo.2019.12.019>.
- Liao C, Huang X, Wang Q, Yao D, Lu W. Virulence Factors of *Pseudomonas Aeruginosa* and Antivirulence Strategies to Combat Its Drug Resistance. *Front Cell Infect Microbiol*. 2022;**12**:926758. [PubMed ID: 35873152]. [PubMed Central ID: PMC9299443]. <https://doi.org/10.3389/fcimb.2022.926758>.

23. Hancock RE, Speert DP. Antibiotic resistance in *Pseudomonas aeruginosa*: mechanisms and impact on treatment. *Drug Resist Updat*. 2000;**3**(4):247-55. [PubMed ID: [11498392](#)]. <https://doi.org/10.1054/drup.2000.0152>.
24. Alamri MS, Alotaibi MA, Ahmad S. Antibiotic Sensitivity Pattern of Clinical Isolates of *Pseudomonas aeruginosa* at a Tertiary Care Hospital in Saudi Arabia. *Dhaka University Journal of Pharmaceutical Sciences*. 2020;**19**(1):77-82. <https://doi.org/10.3329/dujps.v19i1.47821>.
25. Mirzaei B, Bazgir ZN, Goli HR, Iranpour F, Mohammadi F, Babaei R. Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of *Pseudomonas aeruginosa* and *Acinetobacter baumannii* isolated in clinical samples from Northeast of Iran. *BMC Res Notes*. 2020;**13**(1):380. [PubMed ID: [32778154](#)]. [PubMed Central ID: [PMC7418330](#)]. <https://doi.org/10.1186/s13104-020-05224-w>.
26. Choy MH, Stapleton F, Willcox MDP, Zhu H. Comparison of virulence factors in *Pseudomonas aeruginosa* strains isolated from contact lens- and non-contact lens-related keratitis. *J Med Microbiol*. 2008;**57**(Pt 12):1539-46. [PubMed ID: [19018027](#)]. <https://doi.org/10.1099/jmm.0.2008/003723-0>.
27. Galdino ACM, Branquinho MH, Santos AL, Viganor L. *Pseudomonas aeruginosa* and Its Arsenal of Proteases: Weapons to Battle the Host. *Pathophysiological Aspects of Proteases*. 2017. p. 381-97. https://doi.org/10.1007/978-981-10-6141-7_16.
28. Robinson RE, Robertson JK, Moustafa DA, Goldberg JB. piv does not impact *Pseudomonas aeruginosa* virulence in *Galleria mellonella*. *Microbiology Spectrum*. 2025:e02811-24.
29. Fazeli N, Momtaz H. Virulence Gene Profiles of Multidrug-Resistant *Pseudomonas aeruginosa* Isolated From Iranian Hospital Infections. *Iran Red Crescent Med J*. 2014;**16**(10). e15722. [PubMed ID: [25763199](#)]. [PubMed Central ID: [PMC4329751](#)]. <https://doi.org/10.5812/ircmj.15722>.
30. Dadmanesh M, Pilehvarzadeh M, Eramabadi M, Eramabadi P, Moghadam MB, Mashayekhi F. Community Acquired *Pseudomonas aeruginosa* Urinary Tract Infections in Children Hospitalized in a Baqiatallah Hospital, Tehran, Iran: Virulence Profile and Antibiotic Resistance Properties. *Biosciences Biotechnology Research Asia*. 2014;**11**(2):417-26. <https://doi.org/10.13005/bbra/1290>.
31. Shokrzadeh M, Rahbari Jeyd P, Mohammadpour A, Zaboli F, Mohammadnejad FZ, Ghaffari Charati M, et al. [Frequency of *exoT* and *exoS* genes among *Pseudomonas aeruginosa* isolates and antibiotic resistance in burn patients in Sari Zare Hospital, Iran]. *J Mazandaran Univ Med Sci*. 2017;**27**(154):51-9. FA.
32. Wang X, Gao K, Chen C, Zhang C, Zhou C, Song Y, et al. Prevalence of the virulence genes and their correlation with carbapenem resistance amongst the *Pseudomonas aeruginosa* strains isolated from a tertiary hospital in China. *Antonie Van Leeuwenhoek*. 2023;**116**(12):1395-406. [PubMed ID: [37847452](#)]. [PubMed Central ID: [PMC10645663](#)]. <https://doi.org/10.1007/s10482-023-01869-2>.
33. Morgado SM, Bigli NMS, Freitas FS, Rodrigues C, Fonseca EL, Vicente AC. Carbapenem-resistant hypervirulent *P. aeruginosa* coexpressing *exoS/exoU* in Brazil. *J Glob Antimicrob Resist*. 2025;**43**:233-6. [PubMed ID: [40324590](#)]. <https://doi.org/10.1016/j.jgar.2025.04.025>.
34. Ferreira ML, Dantas RC, Faria ALS, Goncalves IR, Silveira de Brito C, Queiroz LL, et al. Molecular epidemiological survey of the quinolone- and carbapenem-resistant genotype and its association with the type III secretion system in *Pseudomonas aeruginosa*. *J Med Microbiol*. 2015;**64**(Pt 3):262-71. [PubMed ID: [25596115](#)]. <https://doi.org/10.1099/jmm.0.000023>.
35. Bogiel T, Depka D, Rzepka M, Kwiecinska-Pirog J, Gospodarek-Komkowska E. Prevalence of the Genes Associated with Biofilm and Toxins Synthesis amongst the *Pseudomonas aeruginosa* Clinical Strains. *Antibiotics (Basel)*. 2021;**10**(3). [PubMed ID: [33670887](#)]. [PubMed Central ID: [PMC7997207](#)]. <https://doi.org/10.3390/antibiotics10030241>.
36. Rather MA, Gupta K, Mandal M. Microbial biofilm: formation, architecture, antibiotic resistance, and control strategies. *Braz J Microbiol*. 2021;**52**(4):1701-18. [PubMed ID: [34558029](#)]. [PubMed Central ID: [PMC8578483](#)]. <https://doi.org/10.1007/s42770-021-00624-x>.